|
ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of neuroscience products maker Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also has other potential oncology treatments in development.
|
| | | Contact Information | |
Address: |
440 Rte. 22 East
Bridgewater, NJ 08807
| | Phone: | 908-541-8100 | | Fax: | |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
President:
Bernhard Ehmer
| | • |
Managing Director and President:
Jerry Kinzel
| | • |
VP and CFO:
Brian Batchelder
|
|
|
Industry Information
| |
Sector: | |
Industry: |
|
|
